European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Cite this article
HE4 - a novel promising serum marker in the diagnosis of ovarian carcinoma
Z. Langmár Langmár1,†,*, M. Németh Németh2,†, G. Vleskó Vleskó1, M. Király Király3, L. Hornyák Hornyák4, P. Bösze Bösze2
1 2nd Department of Obstetrics and Gynecology, Semmelweis University, Budapest
2 Department of Gynecologic Oncology, St. Stephen’s Hospital, Budapest
3 Petz Aladár County Hospital, Györ, 4County Hospital, Veszprém (Hungary)
†These authors contributed equally.
Eur. J. Gynaecol. Oncol. 2011, 32(6), 605–610;
Published: 10 December 2011
Biomarkers have a wide range of applications in the management of several cancers. To date serum markers have been the most extensively used biomarkers in everyday practice but few markers are elevated in preclinical or premalignant disease, limiting their importance for estimating risk or for screening. Human epididymis protein-4 (HE4) is a novel serum marker which is more sensitive in the prediction of risk of ovarian malignancy than CA125 alone in patients with a pelvic mass. HE4 in combination with CA125 appears to be an effective tool for the early detection of recurrence or monitoring the response to therapy. Risk of Ovarian Malignancy Algorithm, utilizing the dual marker combination of HE4 and CA125, can be used to stratify both postmenopausal and premenopausal women into high- and low-risk groups, allowing for an effective triage of women to appropriate institutions for their care. A review of HE4 and its feasibility as a novel diagnostic tool in the management of epithelial ovarian cancer is presented.
Risk of ovarian malignancy algorithm